George S. Golumbeski is an American businessperson who has been at the helm of 6 different companies. Presently, he is Chairman of Aura Biosciences, Inc., Chairman at Carrick Therapeutics Ltd., Chairman at Verseau Therapeutics, Inc. and Venture Partner at ARCH Venture Partners LLC. Dr. Golumbeski is also on the board of 8 other companies.
Dr. Golumbeski previously held the position of Chairman of BioSight Ltd., President & Director at GRAIL, Inc., VP-Business Development, Licensing & Strategy at Novartis AG and VP-Business Development, Licensing & Strategy at Novartis Oncology, Inc. (a subsidiary of Novartis AG), Manager-Technology Acquisition at Promega Corp., Chief Executive Officer at Nabriva Therapeutics GmbH, Executive Vice President-Innovation at Celgene Corp., Vice President-R&D Business Development at Elan Pharmaceuticals LLC, Vice President-Corporate Development of Schwarz Pharma, Inc., Senior Director-Licensing at EMD Pharmaceuticals, Inc. and Director-Business Development of Pierce Biotechnology, Inc.
George S. Golumbeski received an undergraduate degree from the University of Virginia and a doctorate from the University of Wisconsin.